I 

118TH CONGRESS 

1ST SESSION H. R. 5699 

To provide programs to assist diagnosis, awareness, and education of blood 

clot conditions, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

SEPTEMBER 26, 2023 

Ms. BLUNT ROCHESTER (for herself, Mr. BUCSHON, Mr. BURGESS, and Mr. 

TONKO) introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To provide programs to assist diagnosis, awareness, and 

education of blood clot conditions, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Charles Rochester 

5 Blood Clot Prevention and Treatment Act’’. 

6 SEC. 2. FINDINGS. 

7 Congress finds the following: 

8 (1) Deep venous thrombosis (in this Act re9 ferred to as ‘‘DVT’’) occurs when blood clots form 

10 in the legs, pelvis, or arms, and the most serious 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 5699 IH

1 complications occur when a part of the clot breaks 

2 off and travels to the lungs, causing a blockage 

3 called pulmonary embolism (in this Act referred to 

4 as ‘‘PE’’). 

5 (2) According to the Centers for Disease Con6 trol and Prevention, 1 American dies every 6 min7 utes as a result of a blood clot, and 1 in 4 people 

8 who have a PE die without warning. 

9 (3) The Centers for Disease Control and Pre10 vention has estimated that about 900,000 people 

11 suffer from DVT/PE per year and 100,000 people 

12 die each year from blood clots, but also recognizes 

13 that the precise number of people affected by DVT/ 

14 PE is unknown. 

15 (4) These numbers are estimated because cur16 rently there is no systematic collection of DVT/PE17 related morbidity or mortality data in the United 

18 States. 

19 (5) Blood clots can affect anyone, but certain 

20 risk factors make certain individuals more suscep21 tible, including pregnancy, cancer, hospitalizations, 

22 obesity, older age, and African American race. 

23 (6) The overall incidence of DVT and PE is 30 

24 to 60 percent higher in Black Americans, who also 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 5699 IH

1 have a higher rate of 30-day mortality compared 

2 with White Americans. 

3 (7) The direct and indirect cost of blood clots 

4 is more than $10,000,000,000 annually. 

5 (8) Early diagnosis of a DVT is one of the most 

6 important factors in preventing a PE. 

7 SEC. 3. PUBLIC EDUCATION, AWARENESS, AND DIAGNOSIS 

8 OF DVT/PE. 

9 Part J of title III of the Public Health Service Act 

10 (42 U.S.C. 280b et seq.) is amended by inserting after 

11 section 393D the following: 

12 ‘‘SEC. 393E. PREVENTION OF MORBIDITY AND MORTALITY 

13 AS A RESULT OF DEEP VENOUS THROMBO14 EMBOLISM. 

15 ‘‘(a) IN GENERAL.—The Secretary, acting through 

16 the Director of the Centers for Disease Control and Pre17 vention, (in this section referred to as the ‘Secretary’) 

18 shall carry out projects to increase education, awareness, 

19 or diagnosis of deep venous thrombosis (in this section re20 ferred to as ‘DVT’) or pulmonary embolism (in this sec21 tion referred to as ‘PE’) and to reduce the incidence of 

22 morbidity and mortality caused by blood clots. Such 

23 projects may be carried out by the Secretary directly or 

24 through awards of grants or contracts to public or non25 profit private entities. The Secretary may directly (or 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
4 

•HR 5699 IH

1 through such awards) provide technical assistance with re2 spect to the planning, development, and operation of such 

3 projects. 

4 ‘‘(b) PROJECTS.—A project under this section may 

5 include— 

6 ‘‘(1) the implementation of public information 

7 and education programs for— 

8 ‘‘(A) the prevention of death from DVT/ 

9 PE; 

10 ‘‘(B) broadening the awareness of the pub11 lic concerning— 

12 ‘‘(i) the risk factors for and the symp13 toms of DVT/PE; 

14 ‘‘(ii) target populations with greater 

15 risk for DVT/PE, including women, sen16 iors, cancer patients, hospitalized patients, 

17 pregnant and postpartum women, Black 

18 Americans, and those in rural areas; and 

19 ‘‘(iii) the public health consequences 

20 of DVT/PE; and 

21 ‘‘(C) increasing screening, detection, and 

22 diagnosis of DVT/PE; and 

23 ‘‘(2) surveillance of the prevalence and inci24 dence of DVT/PE to improve patient outcomes. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
5 

•HR 5699 IH

1 ‘‘(c) GRANT AND CONTRACT PRIORITIZATION.—The 

2 Secretary may, in awarding grants or entering into con3 tracts under this section, give priority to entities seeking 

4 to carry out projects that target the populations referred 

5 to in subsection (b)(1)(B)(ii). 

6 ‘‘(d) COORDINATION OF ACTIVITIES.—The Secretary 

7 shall ensure that projects carried out under this section 

8 are coordinated, as appropriate, with other agencies of the 

9 Public Health Service that carry out activities regarding 

10 DVT/PE. 

11 ‘‘(e) BEST PRACTICES.—The Secretary shall— 

12 ‘‘(1) collect and analyze the findings of research 

13 conducted with respect to DVT/PE; and 

14 ‘‘(2) taking into account such findings, publish 

15 on the website of the Centers for Disease Control 

16 and Prevention best practices for physicians and 

17 other health care providers who provide care to indi18 viduals with DVT/PE.’’. 

19 SEC. 4. ADVISORY COMMITTEE FOR DVT/PE PREVENTION. 

20 (a) ESTABLISHMENT.—Not later than 180 days after 

21 the date of enactment of this Act, the Secretary of Health 

22 and Human Services (in this section referred to as the 

23 ‘‘Secretary’’) shall establish an advisory committee to be 

24 known as the ‘‘Advisory Committee for DVT/PE PrevenVerDate Sep 11 2014 22:59 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H5699.IH H5699

kjohnson on DSK7ZCZBW3PROD with $$_JOB
6 

•HR 5699 IH

1 tion’’ (in this section referred to as the ‘‘Advisory Com2 mittee’’). 

3 (b) DUTIES.—The Advisory Committee shall— 

4 (1) identify the aggregate number of individuals 

5 in the United States who experience DVT/PE annu6 ally; 

7 (2) identify how data are collected regarding 

8 DVT/PE and the adverse outcomes associated with 

9 such conditions; 

10 (3) identify how DVT/PE impacts the lives of 

11 individuals in the United States; 

12 (4) identify the standard of care for DVT/PE 

13 surveillance, detection, and treatment; 

14 (5) identify emerging treatments, therapies, and 

15 research relating to DVT/PE; 

16 (6) develop recommendations to help health 

17 care providers identify patients who may be at a 

18 higher risk of forming DVT/PE in health care facili19 ties; 

20 (7) develop recommendations to help improve 

21 patient awareness of DVT/PE; 

22 (8) develop recommendations with respect to 

23 the standard of care for patients at risk of forming 

24 DVT/PE; 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
7 

•HR 5699 IH

1 (9) develop recommendations relating to pro2 viding patients and their families with written notice 

3 of increased risks of forming DVT/PE; and 

4 (10) identify the estimated level of Federal 

5 funding needed for DVT/PE services to meet the 

6 needs of high-risk populations. 

7 (c) MEMBERSHIP.—The Advisory Committee shall be 

8 composed of members appointed by the Secretary as fol9 lows: 

10 (1) At least 1 individual who has experienced 

11 blood clots. 

12 (2) At least 1 family member of an individual 

13 who died from DVT/PE. 

14 (3) At least 1 health services researcher. 

15 (4) At least 1 health care provider. 

16 (5) At least 1 representative of a health plan. 

17 (6) At least 1 representative of a hospital or 

18 health system. 

19 (7) At least 1 epidemiologist. 

20 (8) At least 1 public health expert. 

21 (9) At least 1 patient representative or rep22 resentative of a patient group. 

23 (10) Such individuals representing other inter24 ested parties or associations, as the Secretary deter25 mines appropriate. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
8 

•HR 5699 IH

1 (d) REPORT.—Not later than 18 months after the 

2 first meeting of the Advisory Committee, the Secretary 

3 shall submit to Congress (and make publicly available) a 

4 report— 

5 (1) summarizing the meetings and findings of 

6 the Advisory Committee; and 

7 (2) describing the recommendations of the Ad8 visory Committee for legislative or administrative ac9 tion to improve DVT/PE prevention, treatment, and 

10 diagnosis, including the recommendations described 

11 in paragraphs (6) through (9) of subsection (b). 

12 (e) TERMINATION.—The Advisory Committee shall 

13 terminate on the earlier of— 

14 (1) the date on which the Secretary submits the 

15 report under subsection (d); and 

16 (2) the date that is 18 months after the first 

17 meeting of the Advisory Committee. 

18 SEC. 5. DVT/PE SURVEILLANCE STUDY AND REPORT. 

19 (a) STUDY.—The Secretary of Health and Human 

20 Services (in this section referred to as the ‘‘Secretary’’) 

21 shall conduct or support a study on model systems of 

22 DVT/PE surveillance, including the use of electronic med23 ical record-based methods of detecting DVT and PE Inter24 national Classification of Diseases codes (commonly 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
9 

•HR 5699 IH

1 known as ‘‘ICD codes’’) or other population-based surveil2 lance. 

3 (b) REPORT.—Not later than 1 year after the date 

4 of enactment of this Act, the Secretary shall submit to 

5 Congress and the Advisory Committee for DVT/PE Pre6 vention established under section 4(a) a report detailing 

7 the results of the study under subsection (a). 

8 SEC. 6. AUTHORIZATION OF APPROPRIATIONS. 

9 There is authorized to be appropriated to carry out 

10 this section $20,000,000 for each of fiscal years 2025 

11 through 2029. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB